Agomelatine might be more appropriate for elderly, depressed, type 2 diabetes mellitus patients than paroxetine/fluoxetine

Zihong Liang¹, Yanbo Jia², Lizhen Zhao¹, Runxiu Zhu³, Xuemei He¹, Bagen Tong¹, Fan Yang¹, Lixia Hao¹, Pengfei Cui², Jun Yuan³

¹Department of Psychiatry, Inner Mongolia Autonomous Region People’s Hospital, Huhhot, Inner Mongolia 010017, People’s Republic of China
²Department of Orthopaedics, The Second Affiliated Hospital of Inner Mongolia Medical University, Huhhot, Inner Mongolia 010030, People’s Republic of China
³Department of Neurology, Inner Mongolia Autonomous Region People’s Hospital, Huhhot, Inner Mongolia 010017, People’s Republic of China
⁴Department of Psychiatry, Inner Mongolia Autonomous Region Third Hospital, Huhhot, Inner Mongolia 010050, People’s Republic of China

Correspondence to: Jun Yuan; email: junyuaninner@21cn.com, https://orcid.org/0000-0002-3908-6521
Keywords: type 2 diabetes mellitus, depression, agomelatine, paroxetine, fluoxetine
Received: August 6, 2021 Accepted: September 20, 2021 Published: October 5, 2021

Copyright: © 2021 Liang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Agomelatine was a novel and melatonergic antidepressant. The present study was conducted to find out whether age was an important factor for agomelatine in treating depressed type 2 diabetes mellitus (T2DM) patients. In total, 193 depressed T2DM patients were included. There were 84 patients ranged from 27 years old to 49 years old (age phase I) (n = 44 receiving agomelatine, n = 40 receiving paroxetine or fluoxetine), and 109 patients ranged from 50 years old to 70 years old (age phase II) (n = 56 receiving agomelatine, n = 53 receiving paroxetine or fluoxetine). The Hamilton Depression Rating Scale (HDRS) score, Hamilton Anxiety Rating Scale (HARS) score, fasting plasma glucose (FPG), hemoglobin A1c (HbA1c) level and body mass index (BMI) were assessed after 12 weeks treatment. After treatment, we found that among patients in age phase I, there were no significant differences in final average HDRS score, HARS score, FPG, HbA1c level, BMI, response rate and remission rate between the two groups. However, among patients in age phase II, compared to patients receiving paroxetine or fluoxetine, patients receiving agomelatine had the significantly lower average HDRS score, HARS score, HbA1c level and BMI, and significantly higher response rate and remission rate. The incidence of treatment-related adverse events was similar between the two groups in both age phases. These results suggested that age was an important factor for agomelatine in treating depressed T2DM patients. Compared to paroxetine/fluoxetine, agomelatine might be more appropriate for elderly depressed T2DM patients.

INTRODUCTION

Diabetes mellitus (DM) is a common chronic and progressive metabolic disease characterized by notably abnormal glucose metabolism [1–4]. It can cause huge economic burden to individuals and society. Based on World Health Organization (WHO) estimation, the global prevalence of this disease is rising annually, up to about 450 million in 2019 [5]. In China, the number of DM patients is about 116.4 million in 2019, which is the largest such population worldwide [6]. There are two major types of DM: Type 1 and type 2 diabetes; the
later accounts for 90–95% of those with DM [7]. It is estimated that there are a total of 1.6 million DM-related deaths in 2016 [6], and the number is increased to 4 million in 2019 [8].

In addition to early mortality or physical impairments, DM can also negatively impact the mental health of patients. Previous studies found that depression was more frequently diagnosed in DM patients compared to the matched healthy controls; about 15% of DM patients met the criteria for comorbid depression [9, 10]. Depression is a seriously debilitating mental illness with unclear pathogenesis and no objective diagnostic methods [11–13]. The depressed DM patients often show some negative coping strategies that can affect the outcomes of treatment, resulting in the decreased treatment adherence, increased diabetes fatalism and low-quality of life [14]. Therefore, it is important to treat depression in the management of DM.

The efficacy and safety of medications were the two important aspects in clinical application, and researchers have done many works to increase the efficacy and safety of medications [15–17]. Clinicians should be very careful in choosing antidepressants for DM patients, as some medications might be inappropriate for treating depression in DM patients. Clinicians should comprehensively assess the effects of antidepressants on glycemic control, especially in elderly DM patients [18, 19]. Previous studies showed that serotonin reuptake inhibitors (SSRIs) were appropriate for treating depression in DM patients [20, 21]. Fluoxetine was found to be effective in treating depressive symptoms and decreasing blood glucose levels in DM patients [20]. Paile-Hyvärinen et al. reported that paroxetine could effectively mitigate the depressive symptoms and improve glycemic control in DM patients [21]. Recently, a new antidepressant, agomelatine was reported to offer some advantages over SSRIs, such as paroxetine and fluoxetine, in treating the depressed DM patients [22, 23]. However, these studies did not take age into consideration when they obtained such conclusions. Thus, we conducted this study to investigate whether age was an important factor for agomelatine in treating depressed T2DM patients.

**RESULTS**

**Depressive and anxiety symptoms assessment in age phase I**

As shown in Figure 1, the initial average HDRS score was similar between the two groups ($p = 0.75$). After treatment, the average HDRS score was significantly decreased in both groups (experiment group, $p = 2.92E-22$; control group, $p = 1.07E-16$). The final average HDRS score was still similar between the two groups ($p = 0.68$). Meanwhile, the two groups had the similar response rates (43.2% for experiment group and 50.0% for control group, $p = 0.53$) and remission rates (29.5% for experiment group and 37.5% for control group, $p = 0.44$). In addition, the initial average HARS score was similar between the two groups ($p = 0.56$) (Figure 1). After treatment, the average HARS score was significantly decreased in both groups (experiment group, $p = 6.96E-16$; control group, $p = 2.27E-12$). The final average HARS score was still similar between the two groups ($p = 0.16$).

**Depressive and anxiety symptoms assessment in age phase II**

As shown in Figure 2, the initial average HDRS score was similar between the two groups ($p = 0.79$). After treatment, the average HDRS score was significantly decreased in both groups (experiment group, $p = 3.86E-30$; control group, $p = 4.37E-25$). The final average HDRS score was significantly lower in the experiment group than in the control group ($p = 0.0008$). Meanwhile, we found that compared to the control group, the experiment group had the significantly higher response rate (52.8% vs. 73.2%, $p = 0.03$) and remission rate (24.5% vs. 42.9%, $p = 0.04$). In addition, the initial average HARS score was similar between the two groups ($p = 0.96$) (Figure 2). After treatment, the average HARS score was significantly decreased in both groups (experiment group, $p = 2.13E-21$; control group, $p = 7.34E-16$). The final average HARS score was significantly lower in the experiment group than in the control group ($p = 0.0004$).

**Metabolic control assessment in age phase I**

As shown in Figure 3, the initial average FPG level, HbA1c level and BMI were similar between the two groups ($p = 0.72$, $p = 0.88$, $p = 0.45$, respectively). At the end of treatment, the average FPG level was not significantly changed in both groups (Figure 3). Meanwhile, the results showed that the main effect of treatment on the final FPG level was not significant ($p = 0.60$), with similar final average FPG level between the two groups. Meanwhile, we found that the average HbA1c level was significantly decreased in both groups (experiment group, $p = 4.45E-04$; control group, $p = 8.08E-06$) (Figure 3). But the final average HbA1c level was still similar between the two groups ($p = 0.17$). In addition, the average BMI was not significantly changed in both groups (Figure 3), and there was still no significant difference on the final average BMI between the two groups ($p = 0.17$).
Metabolic control assessment in age phase II

As shown in Figure 4, the initial average FPG level, HbA1c level and BMI were similar between the two groups ($p = 0.94$, $p = 0.38$, $p = 0.93$, respectively). At the end of treatment, the average FPG level was not significantly changed in both groups (Figure 4). Meanwhile, the results showed that the main effect of treatment on the final FPG level was not significant ($p = 0.69$), with similar final average FPG level between the two groups. Meanwhile, we found that the average HbA1c level was significantly decreased in both groups (experiment group, $p = 2.58E-15$; control group, $p = 0.003$) (Figure 4). But the final average HbA1c level was significantly lower in the experiment group than in the control group ($p = 8.50E-10$). In addition, we found that the average BMI was significantly increased in the control group after treatment ($p = 0.001$) (Figure 4), and there was significant difference on the final average BMI between the two groups ($p = 0.01$).

Subgroup analysis on gender

Firstly, we analyze the potential gender differences using patients under age phase I. Before treatment, the initial average HDRS score, HARS score, FPG level, HbA1c level and BMI were not significantly different between the two male groups. After treatment, the final average HDRS score, HARS score, FPG level, HbA1c level and BMI were still not significantly different between the two male groups (Figure 5A). The similar results were found between the two female groups (Figure 5B).

Secondly, we analyze the potential gender differences using patients under age phase II. Before treatment, the initial average HDRS score, HARS score, FPG level, HbA1c level and BMI were not significantly different between the two male groups, and also not significantly different between the two female groups. After treatment, the final average HDRS score, HARS score,
HbA1c level and BMI were significantly different between the two male groups (Figure 6A), and the final average HDRS score and HbA1c level were significantly different between the two female groups (Figure 6B).

**Subgroup analysis on depression severity**

Firstly, subgroup analysis on depression severity was conducted using patients under age phase I. Before treatment, the initial average HDRS score, HARS score, FPG level, HbA1c level and BMI were not significantly different between the two moderate depression groups, and also not significantly different between the two severe depression groups. After treatment, the final average HDRS score, HARS score, FPG level, HbA1c level and BMI were still not significantly different between the two moderate depression groups (Figure 7A), but the final average HARS score, HbA1c level

![Graph showing FPG level, HbA1c level and BMI in the two groups (age phase I) before and after treatment. Abbreviations: HbA1c: hemoglobin A1c; FPG: fasting plasma glucose; BMI: body mass index.](image_url)
and BMI were significantly different between the two severe depression groups (Figure 7B).

Secondly, subgroup analysis on depression severity was conducted using patients under age phase II. Before treatment, the initial average HDRS score, HARS score, FPG level, HbA1c level and BMI were not significantly different between the two moderate depression groups, and also not significantly different between the two severe depression groups. After treatment, the final average HARS score, HbA1c level and BMI were significantly different between the two moderate depression groups (Figure 8A), and the final average HDRS score, HARS score, HbA1c level and BMI were significantly different between the two severe depression groups (Figure 8B).

Figure 4. FPG level, HbA1c level and BMI in the two groups (age phase II) before and after treatment. Abbreviations: HbA1c: hemoglobin A1c; FPG: fasting plasma glucose; BMI: body mass index.
Treatment-related adverse events

The used antidepressants in this study were well tolerated. These treatment-related adverse events were observed during the whole treatment period: nausea, headache, dry mouth, diarrhea, anxiety, dizziness, insomnia, suicidal intent, hyperhidrosis, vomiting, sexual side effects and anorexia. The incidence of

![Figure 5. Subgroup analysis on gender (age phase I).](image)

(A) Final average HDRS score, HARS score, FPG level, HbA1c level and BMI in the two male groups. (B) Final average HDRS score, HARS score, FPG level, HbA1c level and BMI in the two female groups. Abbreviations: HDRS: Hamilton Depression Rating Scale; HARS: Hamilton Anxiety Rating Scale; HbA1c: hemoglobin A1c; FPG: fasting plasma glucose; BMI: body mass index; EG: experiment group; CG: control group.

![Figure 6. Subgroup analysis on gender (age phase II).](image)

(A) Final average HDRS score, HARS score, FPG level, HbA1c level and BMI in the two male groups. (B) Final average HDRS score, HARS score, FPG level, HbA1c level and BMI in the two female groups. Abbreviations: HDRS: Hamilton Depression Rating Scale; HARS: Hamilton Anxiety Rating Scale; HbA1c: hemoglobin A1c; FPG: fasting plasma glucose; BMI: body mass index; EG: experiment group; CG: control group.
treatment-related adverse events was not significantly different between the two groups ($p = 0.54$ in age phase I and $p = 0.21$ in age phase II).

**DISCUSSION**

As far as we know, this was the first study to explore whether age was an important factor for agomelatine in treating depressed T2DM patients. At the end of treatment, both treatment methods could significantly decrease the HDRS score, HARS score and HbA1c level in both age phases. In age phase I, the deductions of these indexes were similar in both groups; but in age phase II, the deductions were significantly more in the experiment group than in the control group, and the experiment also had the significantly higher response rate and remission rate. The incidence of treatment-related adverse events was similar between the two groups in both age phases. In addition, in age phase II, compared to control groups, the experiment group had the significantly lower BMI after treatment. The subgroup analyses on gender and depression severity showed the similar results. Therefore, these results indicated that compared to paroxetine/fluoxetine, agomelatine might be more appropriated for depressed T2DM patients under age of 50–70 years old.

Age is a special and important factor in the lifetime of humans, which is characterized with inevitable and internal steady growth. In the different phases of life cycle (young, adult and old), individuals present different biological characteristics and disease risk [24, 25]. Previous studies have suggested that age could affect the microbial composition and functions in the mouse and cynomolgus macaques [26, 27]. Meanwhile, researchers also found the age-specific urinary metabolite signatures and gut microbiota composition in depressed patients [13, 28]. Thus, understanding the different characteristics in different age phases would be helpful for clinicians to prevent and treat diseases.

Depression and anxiety are two kinds of mental disorders, but they share a biological basis. Previous study found that neurotransmitters, such as serotonin and dopamine, played an important role in both depression and anxiety [29]. Depression and anxiety can co-occur, or appear sequentially (one in reaction to the other). Lamers et al. reported that of the patients with a primary anxiety disorder, more than 60% had a current or lifetime depression; similarly, of the patients with a primary depression, more than 65% had a current or lifetime anxiety [30]. Depression and anxiety may be not two kinds of disorders that coexist, but two faces of one. Therefore, to make our conclusion more robust and generalizable, the depression patients with anxiety disorder were also included in this study.

Previous studies found that depression might play a role in the pathogenesis of DM in some ways: i) some environmental stressors resulted in depression and

---

<Figure 7. Subgroup analysis on depression severity (age phase I). (A) Final average HDRS score, HARS score, FPG level, HbA1c level and BMI in the two moderate depression groups. (B) Final average HDRS score, HARS score, FPG level, HbA1c level and BMI in the two severe depression groups. Abbreviations: HDRS: Hamilton Depression Rating Scale; HARS: Hamilton Anxiety Rating Scale; HbA1c: haemoglobin A1c; FPG: fasting plasma glucose; BMI: body mass index; EG: experiment group; CG: control group.>
simultaneously influenced the glucose metabolism [31, 32]; ii) depression could be an independent factor in influencing the nutrition and lifestyle behaviors of patients [31, 32]; iii) depression had a close relationship with the disturbed gut microbiota, and the stable gut microbiota was also important to the health of patients with DM [33–35]; iv) depression could lead to the over-activation of hypothalamic-pituitary-adrenal (HPA) axis and inflammatory response to stress [36, 37]; and the inflammation had an important role in the onset of DM [38–41]. Here, we found that these antidepressants could significantly reduce the HDRS score and HbA1c level in depressed T2DM patients. Therefore, it may be helpful to use antidepressants to treat DM patients with depression.

A meta-analysis showed that the antidepressant modalities were favorable both for depression and diabetes-related parameters [42]. SSRIs are safer for use in depressed DM patients, because they have less antiadrenergic side effects and are free of quinidine-like action. Agomelatine, as a novel and melatonic antidepressant, is marketed for treating depression. Many studies reported that agomelatine was at least as effective as other antidepressants, such as SSRIs, in treating patients with depression [43–45]. Moreover, compared to SSRIs, agomelatine causes less or no discontinuation syndrome and sexual side effects. Here, we found that agomelatine produced better efficacies in depression/anxiety symptoms and metabolic control for patients under the age of 50–70 years old. The clinical applicability of agomelatine in treating elderly depressed T2DM patients showed greater promise and should be further studied.

Several limitations should be noticed here. Firstly, the relatively small number of depressed T2DM patients might weaken the robustness of our results; then our conclusions were needed future studies to validate and support. Secondly, all the included patients were from China and with the same ethnicity, which might limit the generalizability of our findings. Thirdly, the treatment time (12 weeks) was relatively short; then it was unknown that whether our conclusions were appropriate for patients receiving long-term treatment. Fourthly, the information about whether or not the included patients received any non-psychiatric medications was not collected; thus, the interaction effects between non-psychiatric medications and the used antidepressants should be further explored. Fifthly, due to the very small samples of patients with worse glycemic control, we did not assess whether patients with worse glycemic control could fare differently with antidepressant treatment. Finally, only the patients with age < 70 years old were included; then future studies were needed to find out whether our results were similar in patients with age >70 years old.

CONCLUSIONS

In conclusion, the chronicity and high prevalence of depression in T2DM patients, as well as its unpleasant

Figure 8. Subgroup analysis on depression severity (age phase II). (A) Final average HDRS score, HARS score, FPG level, HbA1c level and BMI in the two moderate depression groups. (B) Final average HDRS score, HARS score, FPG level, HbA1c level and BMI in the two severe depression groups. Abbreviations: HDRS: Hamilton Depression Rating Scale; HARS: Hamilton Anxiety Rating Scale; HbA1c: hemoglobin A1c; FPG: fasting plasma glucose; BMI: body mass index; EG: experiment group; CG: control group.
impact on the quality of life and medical outcomes, demonstrated the importance of evidence-based depression treatments. Here, we found that age was an important factor for agomelatine in treating depressed T2DM patients. The clinicians should take age into consideration when using antidepressants, such as agomelatine to treat depressed T2DM patients. Our findings will be helpful for clinicians to make an optimal treatment plan for depressed T2DM patients.

**MATERIALS AND METHODS**

**Included the qualified T2DM patients**

In total, 193 depressed T2DM patients were included, and the treatment methods were obtained from the previous studies [22, 23]. There were 84 patients ranged from 27 years old to 49 years old (age phase I) (*n* = 44 in the experiment group, *n* = 40 in the control group), and 109 patients ranged from 50 years old to 70 years old (age phase II) (*n* = 56 in the experiment group, *n* = 53 in the control group). Patients in the experiment groups received agomelatine 25–50 mg/day, and patients in the control groups received paroxetine 20–40 mg/day or fluoxetine 30–40 mg/day. The doses of the used antidepressants remained unchanged during the whole treatment period. The separate computer-generated random number sequence was used to do randomization. The patients were under standard treatment for diabetes. These patients met the following criteria: i) haemoglobin A1c (HbA1c) >7.0% [46]; ii) 17-item Hamilton Depression Rating Scale (HDRS) was used here to assess the depression severity, and patients with HDRS score ≥ 17 were included; iii) patients were not currently under any psychoactive treatments; iv) without any other psychiatric disorders (not include anxiety disorder), suicidal ideation, serious mental or physical disease; and v) treatment was continued for 12 weeks. The detailed information of these included patients was described in Table 1.

**Outcomes measurement**

To reduce the potential bias, the rater was blind to the drug regimen of patients. The HDRS score, Hamilton Anxiety Rating Scale (HARS) score, HbA1c value, fasting plasma glucose (FPG) and body mass index (BMI) were assessed before treatment and at the end of treatment. Response to drugs was defined as decrease in HDRS score of ≥ 50% from baseline, and remission was defined as a HDRS score of 7 or less. The acceptability of medications was assessed using the number of treatment-related adverse events. In addition, to assess whether our results were appropriate for patients with different genders or patients with different severity of depression, subgroup analyses on gender and severity of depression was conducted. Patients with HDRS value ranged from 17 to 24 were divided in moderate depression group, and patients with HDRS value greater than 24 were divided in severe depression group [47].

**Statistical analyses**

SPSS statistics 19.0 was used to do all the statistical analyses. The mean and standard deviation were used to display the data characterized by a normal distribution. An independent Student’s *t*-test, paired *t*-test, chi-squared test or non-parametric test was conducted when appropriate. If the variables have normal distribution, the Student’s *t*-test was used; if not, the non-parametric test was used. When assessing the differences on final HDRS score, HARS score, HbA1c value, FPG value and BMI between the two groups, we used the analysis of covariance (ANCOVA) method [48]. This method could exclude the effect of parameter’s initial value when we examine the effect of treatment methods on the parameter’s final value. All tests were two-sided and a *p*-value <0.05 was considered as statistically significant.

**AUTHOR CONTRIBUTIONS**

LZH and YJ designed the investigation and wrote the protocol. JYB, ZLZ, ZRX and HXM collected data. TBG, YF, HLX and CPF undertook the statistical analysis. LZH, JYB and ZLZ wrote the original manuscript. YJ modified the original manuscript. All authors contributed to interpretation and approved the final manuscript.
CONFLICTS OF INTEREST

The authors declare no conflicts of interest related to this study.

FUNDING

This project is funded by the Doctoral Research start-up fund of Inner Mongolia Autonomous Region People’s Hospital (Grant No. 2021BS04), the Natural Science Foundation of Inner Mongolia Autonomous Region of China (Grant No. 2020MS03063), the Health Family Planning Research Program of Inner Mongolia Autonomous Region (Grant No. 201703005), the Natural Science Foundation of Inner Mongolia Autonomous Region of China (Grant No. 2016MS0884), and the Foundation Project of the Inner Mongolia Autonomous Region People’s Hospital (Grant No. 201551).

REFERENCES

1. Danna SM, Graham E, Burns RJ, Deschênes SS, Schmitz N. Association between Depressive Symptoms and Cognitive Function in Persons with Diabetes Mellitus: A Systematic Review. PLoS One. 2016; 11:e0160809. https://doi.org/10.1371/journal.pone.0160809 PMID:27526176

2. Kartika R, Purnamasari D, Pradipta S, Larasati RA, Wibowo H. Impact of Low Interferon-γ and IL-10 Levels on TNF-α and IL-6 Production by PHA-Induced PBMCs in Type 2 Diabetes Mellitus. J Inflamm Res. 2020; 13:187–93. https://doi.org/10.2147/JIR.S245064 PMID:32425577

3. Lin S, He W, Zeng M. Association of Diabetes and Admission Blood Glucose Levels with Short-Term Outcomes in Patients with Critical Illnesses. J Inflamm Res. 2020; 13:1151–66. https://doi.org/10.2147/JIR.S287510 PMID:33376380

4. Yin Q, Chen J, Ma S, Dong C, Zhang Y, Hou X, Li S, Liu B. Pharmacological Inhibition of Galectin-3 Ameliorates Diabetes-Associated Cognitive Impairment, Oxidative Stress and Neuroinflammation in vivo and in vitro. J Inflamm Res. 2020; 13:533–42. https://doi.org/10.2147/JIR.S273858 PMID:32982368

5. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, Shaw JE, Bright D, Williams R, and IDF Diabetes Atlas Committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019; 157:107843. https://doi.org/10.1016/j.diabres.2019.107843 PMID:31518657

6. Li J, Qiu X, Yang X, Zhou J, Zhu O, Zhao E, Qiao Z, Yang Y, Cao D. Relationship between Illness Perception and Depressive Symptoms among Type 2 Diabetes Mellitus Patients in China: A Mediating Role of Coping Style. J Diabetes Res. 2020; 2020:3142495. https://doi.org/10.1155/2020/3142495 PMID:33123596

7. American Diabetes Association. Z. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019 (Suppl 1); 42:S13–28. https://doi.org/10.2337/dc19-s002 PMID:30559228

8. Dziedzic B, Sienkiewicz Z, Leńczuk-Gruba A, Kobos E, Fidecki W, Wysokiski M. Prevalence of Depressive Symptoms in the Elderly Population Diagnosed with Type 2 Diabetes Mellitus. Int J Environ Res Public Health. 2020; 17:3553. https://doi.org/10.3390/ijerph17103553 PMID:32438650

9. Golden SH, Lazo M, Carnethon M, Bertoni AG, Schreiner PJ, Diez Roux AV, Lee HB, Lyketsos C. Examining a bidirectional association between depressive symptoms and diabetes. JAMA. 2008; 299:2751–59. https://doi.org/10.1001/jama.299.23.2751 PMID:18560002

10. Katon WJ. The comorbidity of diabetes mellitus and depression. Am J Med. 2008 (Suppl 2); 121:S8–15. https://doi.org/10.1016/j.amjmed.2008.09.008 PMID:18954592

11. Chen X, Lan T, Wang Y, He Y, Wu Z, Tian Y, Li Y, Bai M, Zhou W, Zhang H, Cheng K, Xie P. Entorhinal cortex-based metabolic profiling of chronic restraint stress mice model of depression. Aging (Albany NY). 2020; 12:3042–52. https://doi.org/10.18632/aging.102798 PMID:32074509

12. Wei S, Geng X, Li Z, Xu K, Hu M, Wu H, Shi W, Qiao M. A forced swim-based rat model of premenstrual depression: effects of hormonal changes and drug intervention. Aging (Albany NY). 2020; 12:24357–70. https://doi.org/10.18632/aging.202249 PMID:33229622

13. Chen JJ, He S, Fang L, Wang B, Bai SJ, Xie J, Zhou CJ, Wang W, Xie P. Age-specific differential changes on gut microbiota composition in patients with major
14. Chew BH, Vos RC, Metzendorf MI, Scholten RJ, Rutten GE. Psychological interventions for diabetes-related distress in adults with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2017; 9:CD011469. https://doi.org/10.1002/14651858.CD011469.pub2 PMID:28954185

15. Yarla NS, Pathuri G, Gali H, Terzyan S, Panneerselvam J, Chandrakesan P, Scotti MT, Houchen C, Madka V, Rao CV. Discovery and Development of a Novel mPGES-1/5-LOX Dual Inhibitor LFA-9 for Prevention and Treatment of Chronic Inflammatory Diseases. J Inflamm Res. 2020; 13:1261–78. https://doi.org/10.2147/JIR.S286110 PMID:33408499

16. Azimirad M, Yadegar A, Gholami F, Shahrokhi S, Asadzadeh Aghdae H, Ianiro G, Suzuki H, Cammarota G, Zali MR. Treatment of Recurrent Clostridioides difficile Infection Using Fecal Microbiota Transplantation in Iranian Patients with Underlying Inflammatory Bowel Disease. J Inflamm Res. 2020; 13:563–70. https://doi.org/10.2147/JIR.S265520 PMID:32982371

17. Reddy V, Yang EJ, Myers B, Liao W. Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis. J Inflamm Res. 2020; 13:53–60. https://doi.org/10.2147/JIR.S215196 PMID:32158251

18. Roopan S, Larsen ER. Use of antidepressants in patients with depression and comorbid diabetes mellitus: a systematic review. Acta Neuropsychiatr. 2017; 29:127–39. https://doi.org/10.1017/neu.2016.54 PMID:27776567

19. Leung E, Wongrakpanich S, Munshi MN. Diabetes Management in the Elderly. Diabetes Spectr. 2018; 31:245–53. https://doi.org/10.2337/ds18-0033 PMID:30140140

20. Gülseren L, Gülseren S, Hekimsoy Z, Mete L. Comparison of fluoxetine and paroxetine in type II diabetes mellitus patients. Arch Med Res. 2005; 36:159–65. https://doi.org/10.1016/j.arcmed.2004.12.018 PMID:15847950

21. Paile-Hyvärinen M, Wahlbeck K, Eriksson JG. Quality of life and metabolic status in mildly depressed women with type 2 diabetes treated with paroxetine: a single-blind randomised placebo controlled trial. BMC Fam Pract. 2003; 4:7. https://doi.org/10.1186/1471-2296-4-7 PMID:12747810

22. Kang R, He Y, Yan Y, Li Z, Wu Y, Guo X, Liang Z, Jiang J. Comparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: a double-blind, randomized, clinical trial. Neuropsychiatr Dis Treat. 2015; 11:1307–11. https://doi.org/10.2147/NPT.S58711 PMID:26064049

23. Che T, Teng X, Huang Q, Mu Y, Tang X, Mu X, Wei Y. Agomelatine versus fluoxetine in glycemic control and treating depressive and anxiety symptoms in type 2 diabetes mellitus subjects: a single-blind randomized controlled trial. Neuropsychiatr Dis Treat. 2018; 14:1527–33. https://doi.org/10.2147/NPT.S167608 PMID:29942131

24. Chia CW, Egan JM, Ferrucci L. Age-Related Changes in Glucose Metabolism, Hyperglycemia, and Cardiovascular Risk. Circ Res. 2018; 123:886–904. https://doi.org/10.1161/CIRCRESAHA.118.312806 PMID:30355075

25. Pang L, Liu Y, Shen M, Ye J, Chen R, Lan Z, Wu Z, Guo Y, Zhang P. Influence of aging on deterioration of patients with COVID-19. Aging (Albany NY). 2020; 12:26248–62. https://doi.org/10.18632/aging.202136 PMID:33232272

26. Duan J, Yin B, Li W, Chai T, Liang W, Huang Y, Tan X, Zheng P, Wu J, Li Y, Li Y, Zhou W, Xie P. Age-related changes in microbial composition and function in cynomolgus macaques. Aging (Albany NY). 2019; 11:12080–96. https://doi.org/10.18632/aging.102541 PMID:31837260

27. Scott KA, Ida M, Peterson VL, Prenderville JA, Moloney GM, Izumo T, Murphy K, Murphy A, Ross RP, Stanton C, Dinan TG, Cryan JF. Revisiting Metchnikoff: Age-related alterations in microbiota-gut-brain axis in the mouse. Brain Behav Immun. 2017; 65:20–32. https://doi.org/10.1016/j.bbi.2017.02.004 PMID:28179108

28. Chen JJ, Xie J, Li WW, Bai SJ, Wang W, Zheng P, Xie P. Age-specific urinary metabolite signatures and functions in patients with major depressive disorder. Aging (Albany NY). 2019; 11:6626–37. https://doi.org/10.18632/aging.102133 PMID:31493765

29. Deakin J. The role of serotonin in depression and anxiety. Eur Psychiatry. 1998 (Suppl 2); 13:57s–63s.
30. Lamers F, van Oppen P, Comijs HC, Smit JH, Spinhoven P, van Balkom AJ, Nolen WA, Zitman FG, Beekman AT, Penninx BW. Comorbidity patterns of anxiety and depressive disorders in a large cohort study: the Netherlands Study of Depression and Anxiety (NESDA). J Clin Psychiatry. 2011; 72:341–48. https://doi.org/10.4088/JCP.10m06176blu PMID:21294994

31. Musselman DL, Betan E, Larsen H, Phillips LS. Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. Biol Psychiatry. 2003; 54:317–29. https://doi.org/10.1016/s0006-3223(03)00569-9 PMID:12893107

32. McEwen BS. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev. 2007; 87:873–904. https://doi.org/10.1152/physrev.00041.2006 PMID:17615391

33. Zhao L, Zhang F, Ding X, Wu G, Lam YY, Wang X, Fu H, Xue X, Lu C, Ma J, Yu L, Xu C, Ren Z, et al. Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. Science. 2018; 359:1151–56. https://doi.org/10.1126/science.aao5774 PMID:29590046

34. Li J, Lu H, Wu H, Huang S, Chen L, Gui Q, Zhou W, Yang Y, Wu Y, Zhang H, Zhang Q, Yang Y. Periodontitis in elderly patients with type 2 diabetes mellitus: impact on gut microbiota and systemic inflammation. Aging (Albany NY). 2020; 12:25956–80. https://doi.org/10.18632/aging.202174 PMID:33243730

35. Yu F, Jiang R, Han W, Zhan G, Xu X, Jiang X, Wang L, Xiang S, Zhou Q, Liu C, Zhu B, Hua F, Yang C. Gut microbiota transplantation from db/db mice induces diabetes-like phenotypes and alterations in Hippo signaling in pseudo germ-free mice. Aging (Albany NY). 2020; 12:24156–67. https://doi.org/10.18632/aging.104101 PMID:33223509

36. Geng C, Guo Y, Wang C, Cui C, Han W, Liao D, Jiang P. Comprehensive Evaluation of Lipopolysaccharide-Induced Changes in Rats Based on Metabolomics. J Inflamm Res. 2020; 13:477–86. https://doi.org/10.2147/JIR.S266012 PMID:32904659

37. Liao D, Chen Y, Guo Y, Wang C, Liu N, Gong Q, Fu Y, Fu Y, Cao L, Yao D, Jiang P. Salvianolic Acid B Improves Chronic Mild Stress-Induced Depressive Behaviors in Rats: Involvement of AMPK/SIRT1 Signaling Pathway. J Inflamm Res. 2020; 13:195–206. https://doi.org/10.2147/JIR.S249363 PMID:32494183

38. Fu Z, Mui D, Zhu H, Zhang Y. Exenatide inhibits NF-κB and attenuates ER stress in diabetic cardiomyocyte models. Aging (Albany NY). 2020; 12:8640–51. https://doi.org/10.18632/aging.103181 PMID:32392536

39. Jiang Y, Steinle JJ. Epac1 inhibits PKR to reduce NLRP3 inflammasome proteins in retinal endothelial cells. J Inflamm Res. 2019; 12:153–59. https://doi.org/10.2147/JIR.S210441 PMID:31354329

40. Dar KB, Khan IS, Amin S, Ganie AH, Bhat AH, Dar SA, Reshi BA, Ganie SA. Active Cousinia thomsonii Extracts Modulate Expression of Crucial Proinflammatory Mediators/Cytokines and NFKB Cascade in Lipopolysaccharide-Induced Albino Wistar Rat Model. J Inflamm Res. 2020; 13:829–45. https://doi.org/10.2147/JIR.S272539 PMID:33173324

41. Molla MD, Akalu Y, Geto Z, Dagnew B, Ayelign B, Shibabaw T. Role of Caspase-1 in the Pathogenesis of Inflammatory-Associated Chronic Noncommunicable Diseases. J Inflamm Res. 2020; 13:749–64. https://doi.org/10.2147/JIR.S277457 PMID:33116753

42. Petrak F, Herpertz S. Treatment of depression in diabetes: an update. Curr Opin Psychiatry. 2009; 22:211–17. https://doi.org/10.1097/YCO.0b013e3283207b45 PMID:19553878

43. Kasper S, Hajak G, Wulff K, Hoogendijk WJ, Montejo AL, Smeraldi E, Rybakowski JK, Quera-Salva MA, Wirz-Justice AM, Picarel-Blanchot F, Baylé FJ. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry. 2010; 71:109–20. https://doi.org/10.4088/JCP.09m05347blu PMID:20193645

44. Singh SP, Singh V, Kar N. Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal. Int J Neuropsychopharmacol. 2012; 15:417–28. https://doi.org/10.1017/S1461145711001301 PMID:21859514

45. Taylor D, Sparshatt A, Varma S, Olofinjana O. Antidepressant efficacy of agomelatine: meta-
46. Yu Y, Xie K, Lou Q, Xia H, Wu D, Dai L, Hu C, Wang K, Shan S, Hu Y, Tang W. The achievement of comprehensive control targets among type 2 diabetes mellitus patients of different ages. Aging (Albany NY). 2020; 12:14066–79. https://doi.org/10.18632/aging.103358 PMID:32699183

47. Liu X, Zheng P, Zhao X, Zhang Y, Hu C, Li J, Zhao J, Zhou J, Xie P, Xu G. Discovery and validation of plasma biomarkers for major depressive disorder classification based on liquid chromatography-mass spectrometry. J Proteome Res. 2015; 14:2322–30. https://doi.org/10.1021/acs.jproteome.5b00144 PMID:25784130

48. Lang X, Zhang W, Song X, Zhang G, Du X, Zhou Y, Li Z, Zhang XY. FOXP2 contributes to the cognitive impairment in chronic patients with schizophrenia. Aging (Albany NY). 2019; 11:6440–48. https://doi.org/10.18632/aging.102198 PMID:31425145